



31 March, 2025

Dear Doctor:

I urgently need your help to preserve access to the Rattlesnake Vaccine!

As you know, Red Rock Biologics distributes the Rattlesnake Vaccine (Crotalus Atrox Toxoid). This product is manufactured by our sister company, Hygieia Biological Laboratories - the leading developer of so-called limited market veterinary vaccine products in the United States. Because of their small market nature, such products are typically developed using "conditional" licensing pathways.

Recently, USDA has adopted the novel position that renewal of limited market conditional licenses is time limited - a position which is contrary to their own regulations and guidance documents. Moreover, we are not aware of any actual criteria for limiting licenses in this way. It appears simply arbitrary.

On this basis, USDA has refused to renew several product licenses, including the Rattlesnake Vaccine - the latter despite over twenty years of positive annual reviews and renewals.

The Rattlesnake Vaccine is the first commercial vaccine in the world developed against a venom. It is possibly the most studied veterinary vaccine ever, and there is no credible technical argument against it.

I ask for you to call or write USDA today at the below address to express your support for continued availability of the Rattlesnake Vaccine product. Time is short - we only have a couple of weeks of vaccine supply remaining.

I am tremendously grateful for your help!

Sincerely,

Dale M. Wallis, DVM, Senior Staff Veterinarian
Red Rock Biologics

Geetha Srinivas, DVM, PhD, Director - Center for Veterinary Biologics
1920 Dayton Ave., P.O. Box 844, Ames, IA 50010
Telephone: 515-337-6100 Electronic Mail: geetha.b.srinivas@usda.gov